Alight Introduces GLP-1 HRA Solution to Help Employers Manage Access, Affordability and Cost
Business Wire•13/10/2026•09:01 ET
0
Key Highlights
- ➤Alight launches GLP-1 HRA solution for employer-funded medication reimbursements
- ➤GLP-1 drugs represented 42% of reviewed prescriptions, up from 32% in 2024
- ➤Lower-cost alternatives were available for 16% of reviewed GLP-1 prescriptions
- ➤Lower-cost alternatives delivered average annual savings of $2,790 per GLP-1 drug
Expert Statements
Karen Frost, Senior Vice President, Health and Navigation Solution Leader at Alight
“Employers are looking for practical ways to respond to growing demand for GLP-1 medications while balancing access, affordability and cost management”
Karen Frost, Senior Vice President, Health and Navigation Solution Leader at Alight
“Our solution provides the infrastructure, flexibility and insights to define the support employers want to provide, set clear guardrails and give employees a simpler path to eligible reimbursement.”
Alight Introduces GLP-1 HRA Solution to Help Employers Manage Access, Affordability and Cost
Employer-funded reimbursement model gives organizations more control over eligibility, contributions and plan design
Get started
Create a free account to read the full story.